Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

J. S. Rubin, S. Wadler, Alla Rozenblit, H. Haynes, Hilda Haynes-Lewis, F. McGill, G. Goldberg, C. Runowicz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

Original languageEnglish (US)
Pages (from-to)744-747
Number of pages4
JournalJournal of Laryngology and Otology
Volume109
Issue number8
StatePublished - 1995
Externally publishedYes

Fingerprint

Amifostine
Cisplatin
Radiotherapy
Carcinoma
Poisons
Heavy Metals
Hearing
Neoplasms

Keywords

  • Audiometry
  • Cisplatin
  • Hearing loss, sensorineural
  • Ototoxicity

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. / Rubin, J. S.; Wadler, S.; Rozenblit, Alla; Haynes, H.; Haynes-Lewis, Hilda; McGill, F.; Goldberg, G.; Runowicz, C.

In: Journal of Laryngology and Otology, Vol. 109, No. 8, 1995, p. 744-747.

Research output: Contribution to journalArticle

@article{594bc08f4b974872a2e4ceb38e6d918d,
title = "Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma",
abstract = "WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.",
keywords = "Audiometry, Cisplatin, Hearing loss, sensorineural, Ototoxicity",
author = "Rubin, {J. S.} and S. Wadler and Alla Rozenblit and H. Haynes and Hilda Haynes-Lewis and F. McGill and G. Goldberg and C. Runowicz",
year = "1995",
language = "English (US)",
volume = "109",
pages = "744--747",
journal = "Journal of Laryngology and Otology",
issn = "0022-2151",
publisher = "Cambridge University Press",
number = "8",

}

TY - JOUR

T1 - Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

AU - Rubin, J. S.

AU - Wadler, S.

AU - Rozenblit, Alla

AU - Haynes, H.

AU - Haynes-Lewis, Hilda

AU - McGill, F.

AU - Goldberg, G.

AU - Runowicz, C.

PY - 1995

Y1 - 1995

N2 - WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

AB - WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

KW - Audiometry

KW - Cisplatin

KW - Hearing loss, sensorineural

KW - Ototoxicity

UR - http://www.scopus.com/inward/record.url?scp=0029160835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029160835&partnerID=8YFLogxK

M3 - Article

VL - 109

SP - 744

EP - 747

JO - Journal of Laryngology and Otology

JF - Journal of Laryngology and Otology

SN - 0022-2151

IS - 8

ER -